Trials / Completed
CompletedNCT05890053
To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia
A 52-week, Open Phase III Study Evaluating the Long-term Safety and Efficacy of HSK16149 Capsules in Chinese Patients With Peripheral Neuralgia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 301 (actual)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Investigate the long-term(52 weeks) safety and efficacy of HSK16149 capsules in Chinese patients with periphcral neuralgia
Detailed description
Investigate the long-term(52 weeks) safety and efficacy of HSK16149 capsules in Chinese patients with Peripheral neuropathic pain
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK16149 40mg BID | HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose. |
Timeline
- Start date
- 2022-02-17
- Primary completion
- 2023-07-30
- Completion
- 2023-08-07
- First posted
- 2023-06-06
- Last updated
- 2025-09-04
Locations
24 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05890053. Inclusion in this directory is not an endorsement.